Durect Corp.'s second attempt to gain approval for a surgical pain treatment may hinge on a product characteristic that the US Food and Drug Administration identified as problematic during its first assessment of the application.
Bupivacaine extended-release solution, known as Posimir, is proposed for post-surgical analgesia to be accomplished by administration through instillation into the...





